secwatch.observer — SEC 8-K summary
======================================

Issuer:     Definium Therapeutics, Inc. (DFTX)
CIK:        0001813814
Form:       8-K
Filed at:   2024-06-20T23:59:59+00:00
Accession:  0000950170-24-075317
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MindMed reaches alignment with FDA on Phase 3 plan for MM120 in GAD
-------------------------------------------------------------------

- Constructive End-of-Phase 2 meeting with FDA; aligned on Phase 3 requirements for MM120 (LSD D-tartrate) in generalized anxiety disorder.
- Phase 3 program initiation remains on schedule for second half of 2024.
- Phase 2b MMED008 trial results: MM120 100 µg cohort showed 65% clinical response rate and 48% remission rate on HAM-A at Week 12.
- Last new FDA approval for GAD was in 2007; no robust treatment options have emerged since.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1813814/000095017024075317/0000950170-24-075317-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1813814/000095017024075317/mnmd-20240620.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-075317

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer